QTTB MEXC RealStocks
Own real QTTB shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-15 11:38:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Q32 Bio Inc. (QTTB) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $8.72, with a market capitalization of $260.64M and a P/E ratio of 8.08. Over the past 52 weeks, its price has ranged from $1.91 to $23.57. This page covers its latest market performance, valuation, price trends and company information.
$260.64M | |
$8.83 | |
$8.94 | |
$8.33 | |
$8.82 | |
216.52K | |
692.84K | |
8.08 | |
$23.57 | |
$1.91 | |
-- | |
-- |
Q32 Bio Inc. (QTTB) last closed at $8.72 as of 2026-11-14 00:58:00, down 0.96% ($0.09) from the previous close of $8.82.
During the latest regular trading session, QTTB traded between $8.33 and $8.94, with a volume of 216.52K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Q32 Bio Inc. (QTTB) moved from $8.85 to $8.72, representing a decline of 1.48% ($0.13).
The stock traded between $8.23 and $9.74 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 338.84 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 31.5%
QTTB is currently trading at $8.72, placing it 31.5% of the way from its 52-week low of $1.91 to its 52-week high of $23.57. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 25 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Q32 Bio Inc. (QTTB) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to QTTB, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between QTTB shares and USD.
QTTB Shares to USD
1.00 QTTB shares = 8.719 USD
Calculations are estimates based on the latest available price and are for reference only.